ARH 047108Alternative Names: RAPID
Latest Information Update: 16 Aug 2002
At a glance
- Originator AstraZeneca
- Mechanism of Action Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 25 Jul 2002 Discontinued - Phase-II for Gastrointestinal disorders in Europe (unspecified route)
- 20 Dec 2000 Phase-II clinical trials for Gastrointestinal disorders in Europe (Unknown route)
- 07 Feb 2000 New profile